An observational study in Multiple Sclerosis, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Multiple Sclerosis with a site in Switzerland — 25 open to participants now, 37 under way, 8 of them phase 3. Multiple Sclerosis · Switzerland.
Among the 143 studies in Multiple Sclerosis with a site in Switzerland, this one is the 42nd largest by planned enrollment of the 57 observational ones that give a count, is one of 8 that started in 2026, is one of 57 observational ones, reaches primary completion later than 9 of the 36 other live ones, and was the 140th registered.
3,272 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.
Browse Multiple Sclerosis studies →25 of the 143 studies in Multiple Sclerosis with a site in Switzerland are open now. Recruiting first, the newest first:
Klinik Valens · Sites in Switzerland
Ages 18+
Liliana Barrios · Sites in Switzerland
Ages 18–65 · Healthy volunteers
Klinik Valens · Sites in Switzerland
Ages 18+
Prof. Arseny Sokolov, MD, PhD · Sites in Switzerland
Ages 18+
Luzerner Kantonsspital · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 31 · Phase 4 10
First in 2002; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 141 across the 86 interventional studies, 182 across the 57 observational. Of the 96 that completed or were terminated, 37 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 143 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 9 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Multiple Sclerosis with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT06854094Ente Ospedaliero Cantonale, BellinzonaConsolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients | 2026-12 |
| NCT05009160Research Center for Clinical Neuroimmunology and Neuroscience BaselDreaMS - Validation Study 1 | 2026-12 |
| NCT05357781Insel Gruppe AG, University Hospital BernImmunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 143 studies in Multiple Sclerosis with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).
The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.
MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.
The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.
Moreover, the study will assess the safety of TBE vaccination.
The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.
In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Suspected neuroimmunological disorder with CNS affection
TBE vaccine:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).
Primary immunogenicity endpoint
Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA
Time frame: 42 days post dose 1
Immunogenicity endpoint
Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)
Time frame: 42 days post dose 1
Immunogenicity endpoint
Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.
Time frame: 7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.
Time frame: 7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration \>150 U/ml for ELISA.
Time frame: at each time point (7 months)
Immunogenicity endpoint
Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer \>1:10 for SNT.
Time frame: at each time point (7 months)
Safety endpoint
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.
Time frame: 42 (+/-7d) post dose 1
Safety endpoint
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)
Time frame: 42 (+/-7d) post dose 1
Safety endpoint
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Neurological assessment (EDSS)
Time frame: 42 (+/-7d) post dose 1
Safety endpoint
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)
Time frame: 42 (+/-7d) post dose 1
Safety endpoint
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 \- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)
Time frame: 42 (+/-7d) post dose 1
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.
Of 335 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 13 months is below that.
Counting every sponsor, half of 426 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →